Metsera Completes Sale to Pfizer in Deal Worth Up to $10 Billion

Paul, Weiss advised Metsera, a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and cardiometabolic diseases, in its sale to Pfizer. Under the terms of the deal, Pfizer acquired Metsera for up to $86.25 per share, consisting of $65.60 per share in cash and a contingent value right (CVR) entitling holders to additional payments of up to $20.65 per share in cash, bringing the total value of the deal to approximately $10 billion. Metsera is now a wholly owned subsidiary of Pfizer, and its common stock has ceased trading on the NASDAQ Global Select Market.

The Paul, Weiss team was led by corporate partners Benjamin Goodchild, Andrew Krause and Scott Barshay, and included partners John Kennedy, Tim Cruickshank, Patricia Vaz de Almeida and counsel Lyudmila Bondarenko; executive compensation partner Matthew Friestedt, and counsel Cynthia Akard and Annie Anderson; tax partners Brian Krause and Anne McGinnis; antitrust partners Scott Sher and Nicole Kar, and counsel Lauren O’Brien, John Magruder, Todd Hahn and Robert O’Loughlin; litigation partners Geoffrey Chepiga, Jaren Janghorbani, Jay Cohen, William Michael, Paul Brachman, Andre Bouchard and Daniel Mason, and counsel Marques Tracy, Conrad Scott and Audrey Paquet; and intellectual property partners Jonathan Ashtor and Jeffrey Osterman and counsel Matthew Rosenberg.